StockNews.com Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

Investment analysts at StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a report issued on Saturday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

CPIX opened at $2.32 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.99 and a current ratio of 1.13. The stock has a market capitalization of $32.58 million, a price-to-earnings ratio of -3.01 and a beta of 0.30. The company has a fifty day moving average of $1.51 and a 200 day moving average of $1.43. Cumberland Pharmaceuticals has a fifty-two week low of $1.04 and a fifty-two week high of $3.05.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.